Business
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring s
About this update from Neonc Technologies Holdings, Inc.
[{"type":"image","alt":"NeOnc Technologies Holdings, Inc.","displaySize":"","headline":null,"caption":"NeOnc Technologies Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/b347a68adadea2a3bd45b7a77e70bf38"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o4p8_hWKHEoe_S6DjNy.mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMA--/https://media.zenfs.com/en/globenewswire.com/b347a68adadea2a3bd45b7a77e70bf38","width":300,"height":93}},"lazy":false},{"type":"text","content":"CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring strong alignment with shareholders ahead of upcoming clinical and regulatory milestones.","length":587,"tagName":"p"},{"type":"text","content":"Over the past year, Mr. Heshmatpour has invested nearly $1 million of personal capital into NeOnc shares. In recent weeks, he has purchased over $500,000 of additional stock in the open market, as reflected in Form 4 filings with the U.S. Securities and Exchange Commission, with further purchases anticipated.","length":310,"tagName":"p"},{"type":"text","content":"“We are entering a defining phase for NeOnc, with near-term data readouts and regulatory alignment that we believe could meaningfully reshape the treatment landscape for aggressive brain cancers,” said Mr. Heshmatpour. “My continued open-market purchases reflect my conviction not only in our upcoming catalysts, but in the long-term potential of our platform to overcome the blood-brain barrier and improve patient outcomes where current therapies fall short.”","length":461,"tagName":"p"},{"type":"text","content":"NeOnc recently reported completion of NEO212’s Phase 1 dose escalation and established a recommended Phase 2 dose, while its Phase 2a study of NEO100 in recurrent IDH1-mutant high-grade glioma remains fully enrolled with an interim analysis expected later this year.","length":266,"tagName":"p"},...